|
市場調查報告書
針對藥品開發的醫療化學：近年來動向的重要性
Medicinal Chemistry for Drug Discovery: Significance of Recent Trends
|
針對藥品開發的醫療化學：近年來動向的重要性 是由出版商Insight Pharma Reports在2009年03月所出版的。
這份英文市場調查報告書包含170 pages 價格從美金3195起跳。
本報告書內容包括：針對藥品開發研究效率相關合作及委外動向、針對藥品開發的醫療化學方針及方法論、技術及市場動向等。內容綱要摘記如下：
第1章 介紹
第2章 藥品產業的有機・醫療化學發展
第3章 針對藥品開發的有機・醫療化學技術
- 電腦・藥品設計
- 藥品設計的多樣化取向
- 利用天然產品的藥品設計
- 化學基因體學及藥品設計
- 未來預測
第4章 藥品開發中有機・醫療化學的應用
- 委外服務企業的技術方針概要
- 藥品開發委外服務企業的服務概要
- 利用結構的藥品設計
- 利用片段的藥品設計
- 利用天然產品的藥品設計
- 藥品設計的多樣化取向
- 虛擬篩檢
第5章 市場動向
- 委外動向
- 醫療化學領域中活躍的化學人員・管理人員調查
第6章 結論及未來動向
第7章 專家訪談
參考資料
Abstract
A thorough analysis of recent trends in medicinal chemistry and evaluation of
their significance for advancing productivity in drug discovery is presented.
This report includes:
- A critical evaluation of chemical and computational technological
modalities, their current and potential value, and their commercial
manifestations.
- A consideration of market dynamics with an emphasis on outsourcing and
user views on the implications of current practices in drug discovery
organizations.
- Insights gleaned from an extensive literature review, discussions with
industry experts, and an opinion survey of personnel active in medicinal
chemistry for drug discovery.
- Medicinal Chemistry for Drug Discovery: Significance of Recent Trends
reviews the state of the art and aims to determine the significance of
technology and market trends in medicinal chemistry for advancing productivity
in drug discovery. Although the fundamental task of medicinal chemists has not
changed drastically over time, the chemical and computational tools and
perspectives at their disposal have advanced significantly. One in particular,
fragment-based drug design, stands out as promising major improvements in
research productivity.
We examine medicinal chemistry-related approaches and methodologies that drug
discovery organizations employ in an effort to increase productivity in early
drug discovery and decrease attrition at later pipeline stages. Key topics
considered include structure-based drug design, fragment-based drug design,
natural products-based drug design, diversity-oriented synthesis, and
chemogenomics. An overall assessment of the current and potential value of
these approaches is presented. Various flavors of computer-aided drug design
are also considered, as the complexity and limitations of drug discovery
programs that are based on biochemical screens of large compound collections
have been major factors in stimulating the growth of this modality.
Each of the aforementioned technological modalities is viewed in terms of
practical examples and commercial activity. Outsourcing arises as a prominent
theme in the applications realm, with special emphasis on companies with
primary operations in countries with developing economies, notably China,
India, and Russia. Among 32 companies considered, structure-based drug design
is the most prevalent activity with most players emphasizing the
fragment-based variation. Virtual screening is the second-most prevalent
modality, whereas natural products, diversity-oriented synthesis, and
chemogenomics appear in only a small minority of cases.
Outsourcing vendors are viewed according to participation in hit discovery,
hit-to-lead synthesis, lead optimization, library synthesis, in-house drug
discovery, and virtual drug design. More than one-third of the companies
considered have operations primarily located in countries with emerging
economies. A large majority of companies offer computer-based services,
hit-to-lead, lead optimization, and library synthesis. Fewer engage in hit
discovery, and a small minority do their own drug discovery.
Medicinal Chemistry for Drug Discovery: Significance of Recent Trends next
examines deal activity and the influence of outsourcing on research
productivity. Results from a survey of managers and researchers active in the
field provide a multifaceted picture of practices and attitudes prevalent in
drug discovery organizations today. Conclusions from the user survey highlight
which modalities are viewed as having greater potential to make an impact on
productivity. Finally, the complete transcripts of seven interviews with
experts in the field are provided.
Table of Contents
Chapter 1 INTRODUCTION
- 1.1. Background
- 1.2. Scope and Nature of the Report
Chapter 2 EVOLUTION OF ORGANIC AND MEDICINAL CHEMISTRY IN PHARMA
- 2.1. Pharmaceutical Trends over Time
- 2.2. Combinatorial Chemistry
- 2.3. Lipinski' s Rule of Five
- 2.4. Impact of Lipinski' s Rule of Five
Chapter 3 ORGANIC AND MEDICINAL CHEMISTRY TECHNOLOGIES FOR DRUG DISCOVERY
- 3.1. Computer-Aided Drug Design
- Virtual Screening
- Target Structure-Based Design
- Ligand Structure-Based Design
- De Novo Compound Design
- QSAR (Quantitative Structure-Activity Relationship)
- Fragment-Based Drug Design
- 3.2. Diversity-Oriented Synthesis in Drug Design
- 3.3. Natural Products-Based Drug Design
- 3.4. Chemogenomics and Drug Design
- 3.5. Perspectives
Chapter 4 APPLICATIONS OF ORGANIC AND MEDICINAL CHEMISTRY IN DRUG DISCOVERY
- 4.1. Overview of Technology Approaches of Outsourcing Vendors
- 4.2. Overview of Service Offerings by Drug Discovery Outsourcing Vendors
- 4.3. Structure-Based Drug Design
- 4.4. Fragment-Based Drug Design
- 4.5. Natural Products-Based Drug Discovery
- 4.6. Diversity-Oriented Synthesis in Drug Discovery
- 4.7. Virtual Screening
Chapter 5 MARKET DYNAMICS
- 5.1. Outsourcing Dynamics
- 5.2. Survey of Chemists and Managers Active in Medicinal Chemistry
Chapter 6 CONCLUSIONS AND FUTURE TRENDS
- 6.1. Optimizing the Interplay of Chemistry and Biology
- 6.2. Effects of the �gIndustrialization�h of Drug Discovery
Chapter 7 EXPERT INTERVIEWS
- 7.1. Christopher Lipinski, PhD
- Drug Discovery Consultant, Retired Senior Research Fellow, Pfizer
- 7.2. Celerino Abad-Zapatero, PhD
- Adjunct Professor, University of Illinois at Chicago, Center for
Pharmaceutical Biotechnology
- 7.3. Medicinal Chemistry Executive
- Anonymous; Veteran from Big Pharma
- 7.4. Gilbert Rishton, PhD
- Founder and Director, Alzheimer' s Institute, California State University
Channel Islands
- 7.5. Steven Muskal, PhD
- 7.6. Informatics Chemist
- 7.7. Sidney Topiol, PhD
- Associate Director, Computational Chemistry, Lundbeck Research
References
- Company Index with Web Addresses
|
